Global data are in the same ballpark as Chinese results presented earlier this year.

The group cans ZW171 after “on-target, off-tumour toxicity”.

It’s a new term for biotech and its investors.

China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.

Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.

Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.

A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.

The company gets another odronextamab knockback, while a key fianlimab readout is postponed.

Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.

Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.